- Home
- TYG vs PRCT Comparison
TYG vs PRCT Comparison
Compare TYG & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TYG | PRCT |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TYG | PRCT |
|---|---|---|
| Price | $43.12 | $19.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $35.44 |
| AVG Volume (30 Days) | 108.8K | ★ 947.9K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 11.71% | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | N/A | $24.52 |
| P/E Ratio | $52.62 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $40.35 | $16.67 |
| 52 Week High | $51.18 | $40.10 |
Technical Indicators
Market Signals| Indicator | TYG | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 57.37 | 50.43 |
| Support Level | $42.23 | $19.87 |
| Resistance Level | $45.31 | $22.88 |
| Average True Range (ATR) | 0.68 | 1.05 |
| MACD | 0.06 | -0.12 |
| Stochastic Oscillator | 75.54 | 44.75 |
Price Performance
Historical ComparisonAbout TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.